We upgrade AVO to OUTPERFORM with a fair value of 155 GBp. The company has significant growth potential in the nascent Proton therapy ("PT") industry. The dented growth trajectory from the industry leaders in PT signals the limitation of the conventional cyclotron technology in PT. We are encouraged by AVO's technology to benefit from this bottleneck through delivery of a better and easier-to-install technology with its PT Linac. Execution on scaling up production will easily lower machine pr
26 Apr 2018
Revamped particle therapy story
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Revamped particle therapy story
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
26 Apr 2018 -
Author:
Martin Brunninger -
Pages:
57
We upgrade AVO to OUTPERFORM with a fair value of 155 GBp. The company has significant growth potential in the nascent Proton therapy ("PT") industry. The dented growth trajectory from the industry leaders in PT signals the limitation of the conventional cyclotron technology in PT. We are encouraged by AVO's technology to benefit from this bottleneck through delivery of a better and easier-to-install technology with its PT Linac. Execution on scaling up production will easily lower machine pr